DJ EQS-News: Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer
EQS-News / 15/10/2020 / 15:01 UTC+8
Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai:
Dedicated to the Research and Development of Innovative Therapies for Cancer
Shanghai, China, October 12, 2020-Antengene Corporation, a leading
innovative biopharmaceutical company dedicated to discovering, developing
and commercializing global first-in-class and/or best-in-class therapies in
oncology and hematology, announced today, the official opening of the
Antengene's New Drug Discovery Center based in Zhangjiang, Shanghai. The
opening ceremony and historic event held in Zhangjiang Hi-Tech Park was
attended by Mr. Jun Wu, Deputy Director of Zhangjiang Administration of
China (Shanghai) Pilot Free Trade Zone, Mr. Tao Yuan, Chairman of Shanghai
Zhangjiang Group, Ms. Qi Lou, General Manager of Zhangjiang Biomedical Base,
Mr. Shaoxiong Du, Director of Zhangjiang Investment Service Center, Mr.
William Hu, Managing Partner of Qiming Venture Partners, Mr. Yilun Liu, Vice
President of Boyu Captical, Dr. Xiaoping Ye, Chairman of Tigermed Group, Mr.
Edward Hu, Vice Chairman and Global Chief Investment Officer of WuXi AppTec,
Dr. Chris Chen, CEO of WuXi Biologics, Dr. Huanfeng Yang, CEO of Origincell
Bio-Technology, Dr. Honggang Bi, General Manager of Covance China and Dr.
Xiaoyong Fu, Senior Vice President of STA Pharmaceutical.
As a leading clinical-stage Asia-Pacific biopharmaceutical company focused
on innovative oncology medicines, Antengene aims to extend patients' lives
and improve their quality of life, through new drug discovery, development,
and dedicating itself to providing innovative anti-cancer therapies for
patients in China, Asia-Pacific and around the world. Shanghai Zhangjiang
Hi-Tech Park is a highlight in the history of Pudong's reform and
development. R&D resources are highly concentrated, and innovative
achievements are rapidly emerging. With its continuously influx of talented
scientists and industry professionals and technology platform advantages, it
is leading the development of China's biomedical industry.
Antengene's New Drug Discovery Center, established in Zhangjiang, Shanghai,
will build a platform for targeted-based screening and lead drug discovery
by capitalizing on the talented scientists and technical advantages of
"Chinese Pharma Valley", and focus on potential first-in-class or
best-in-class innovative anti-cancer drugs based on complete upstream and
downstream industrial chains of the park. At present, the Drug Discovery
Center is equipped with a small molecule formulation R&D laboratory, an
antibody discovery laboratory, cell culture chambers, and has introduced
state-of-art devices such as spectral flow cytometry, automatic protein
purification system and high-resolution fluorescence microscope.
"Located in Zhangjiang and capitalising on the advantages of the Zhangjiang
pharmaceutical sector, Antengene Drug Discovery Center will continue to
discover and develop potential first-in-class or best-in-class novel
anti-cancer medicines, strengthen and complement our pipeline and take full
advantage of the potential of combination treatment." Dr. Jay Mei, founder,
chairman and CEO of Antengene, said, "Discovery is beyond borders, and
innovation is never-ending. In Zhangjiang, we will jointly explore the
establishment of an innovative discovery center and collaborate with other
pharmaceutical companies and the talent in the area. We believe that
Antengene's professional and experienced scientists will discover more and
newer innovative therapies faster. Through our joint efforts, we will
benefit patients as soon as possible. "
About Antengene
Antengene is a biopharmaceutical company with integrated drug discovery,
clinical development, anchored in Asia Pacific with a global layout.
Antengene aims to provide the most advanced anti-cancer drugs to patients in
China, the rest of Asia Pacific and around the world. Since official
operation in April 2017, Antengene has built a pipeline of 12 clinical and
pre-clinical stage assets, obtained 9 IND approvals and has 9 ongoing
cross-regional clinical trials in Asia Pacific. At Antengene, we focus on
developing drug candidates with novel MoAs and first-in-class/best-in-class
potential to address significant unmet medical needs. The vision of
Antengene is to "Treat Patients Beyond Borders" through research,
development and commercialization of first-in-class/best-in-class
therapeutics.
Forward-looking statement
The forward-looking statements made in this article relate only to the
events or information as of the date on which the statements are made in
this article. Except as required by law, we undertake no obligation to
update or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise, after the date on
which the statements are made or to reflect the occurrence of unanticipated
events. You should read this article completely and with the understanding
that our actual future results or performance may be materially different
from what we expect. In this article, statements of, or references to, our
intentions or those of any of our Directors or our Company are made as of
the date of this article. Any of these intentions may alter in light of
future development.
File: Antengene's New Drug Discovery Center Established in Zhangjiang,
Shanghai: Dedicated to the Research and Development of Innovative Therapies
for Cancer [1]
15/10/2020 Dissemination of a Financial Press Release, transmitted by EQS
Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9598c00fd4f837ef8c731394700d155b&application_id=1141027&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 15, 2020 03:01 ET (07:01 GMT)
© 2020 Dow Jones News
